


PhenoSense HIV Entry Assay

Envelope Expression Vector: pHIVenv



HIV-1 Expression Vector: pHIVluc Δ U3




Fig. 1A

PhenoSense™ HIV: Cell Assay




Fig. 1B



Co-Receptor Tropism Screen

CCR5-expressing cells






Fig. 3A

Replicate 2

Replicate 1



CXCR4-expressing cells

Co-Receptor Tropism Assay Interpretation




Fig. 3B



Entry Inhibitor Susceptibility: Fusion Inhibitor





Fig. 4A



Reduced Susceptibility: Fusion Inhibitor




Fig. 4B



Entry Inhibitor Susceptibility: CCR5 Inhibitor




Fig. 5A

Drug: R5 Inhibitor
Cell: CD4/CCR5



205260 2002007

Entry Inhibitor Susceptibility: CXCR4 Inhibitor





Fig. 5B

Drug: X4 Inhibitor
Cell: CD4/CXCR4



Envelope Sequence Amplification



1 2 3 4 5 6

Co-Receptor Tropism

X4
R5
X4/R5
Undefined

of isolates

15
24
15
35

Envelope Subtype

Clade A
Clade B
Clade C
Clade D
Clade E


of isolate

2
76
7
1
3

Fig. 6

Target Cell Receptor and Co-Receptor Expression

Fig. 7



Inhibition By Co-Receptor Antagonists




Fig. 8

Fusion Inhibitor Peptides




Fig. 9

Rimsky, et al., J. Virol. 72 (2):986-993



Patient Virus v. Patient Antibody

Virus Date	Plasma (Antibody) Date									
	9/2/99	11/29/99	2/29/00	5/31/00	8/30/00	11/22/00	2/14/01	5/30/01	9/11/01	
9/2/99	26	219	675	1403	2670	2089	2190	2363	2411	
11/29/99	29	179	1024	2151	3733	3152	2808	2953	3086	
2/29/00	27	35	78	358	1769	1939	2247	3112	4345	
5/31/00	36	67	82	200	795	1078	1371	2208	3375	
8/30/00	19	48	36	64	76	166	556	937	1407	
11/22/00	29	43	64	76	90	119	374	721	1234	
2/14/01	42	65	61	152	117	134	122	289	526	
5/30/01	41	66	82	84	85	113	78	107	296	
9/11/01	42	62	56	62	85	77	55	61	95	
Reference Virus										
NL43	17	138	294	956	1172	953	1584	1868	2143	
JRCSL	24	37	35	60	87	97	105	152	209	

Fig. 10

